Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

AbC-19 rapid antibody test performance evaluation

9 Jul 2021 09:08

RNS Number : 7496E
Omega Diagnostics Group PLC
09 July 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

AbC-19TM rapid antibody test performance evaluation

Peer-reviewed performance evaluation and self-test user experience of AbC 19TM

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes

the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, welcoming the publication of two peer-reviewed studies conducted by Ulster University and involving AbC-19™, a lateral flow test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus.

 

Highlights from the studies include:

· Excellent laboratory validation performance metrics for the AbC-19™ rapid test for SARS-CoV-2 spike protein IgG antibody detection and semi-quantitative correlation withlaboratory ELISA methods assaying IgG antibodies to the spike protein of the SARS-CoV-2 virus.

· AbC-19™ showed sensitivity of 97.58% and specificity of 99.59% when using evaluation methods as defined by the MHRA for Target Product Profile of an antibody test.

· In addition, the study notes that IgG antibodies to the SARS-CoV-2 virus were detected 10 months after infection. Understanding the longevity of COVID-19 antibodies is importantboth immunologically and in helping to guide pandemic exit protocols.

· Positive user experience score from 1,544 participants who used AbC-19™ as a 'self-test'

 

Professor Chris Molloy, Independent chairman of the UK Rapid Test Consortium said: "We are entering a phase of the pandemic where testing for immunity will become as or more important than testing for infection. Rapid, accurate immunity tests are therefore a critical tool for citizens and public health providers to embrace. 

 

"Development of multiple antibody tests, and semi-quantitative approaches will enhance this portfolio and enable the most rapid global recovery."

 

The UK-RTC press release can be read in full here: 

https://www.abc19.com/peer-reviewed-performance-evaluation-and-self-test-user-experience-of-abc-19/

 

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAPXNEEKFEEA
Date   Source Headline
16th Jul 20127:00 amRNSDirector/PDMR Shareholding
9th Jul 20124:35 pmRNSDirector/PDMR Shareholding
6th Jul 201210:37 amRNSDirector Dealing
6th Jul 20127:00 amRNSGrant of Options
2nd Jul 20127:00 amRNSFinal Results
19th Jun 20127:00 amRNSCollaboration with the Burnet Institute, Melbourne
16th Apr 20127:00 amRNSTrading Statement
2nd Apr 201210:51 amRNSDirector Shareholding
28th Mar 20123:08 pmRNSDirectorate Change
30th Jan 201211:57 amRNSDirector/PDMR Shareholding
17th Jan 20129:00 amRNSDirectorate Change
25th Nov 20117:00 amRNSInterim Results
7th Nov 20117:00 amRNSChange of Adviser
10th Oct 20117:00 amRNSTrading Update & Notice of Results
23rd Aug 201111:29 amRNSResult of AGM
15th Aug 20112:05 pmRNSDirector/PDMR Shareholding
4th Jul 20117:00 amRNSFinal Results
30th Jun 20111:18 pmRNSDirectorate Change
27th May 201111:58 amRNSHolding(s) in Company
24th May 20117:00 amRNSTen year exclusive distribution agreement
12th Apr 20117:00 amRNSTrading Update & Management Appointments
28th Mar 20117:35 amRNSExclusive Licence Agreement
23rd Feb 20119:20 amRNSHolding(s) in Company
17th Jan 20117:00 amRNSHolding(s) in Company
23rd Dec 201010:53 amRNSHolding(s) in Company
23rd Dec 201010:53 amRNSHolding(s) in Company
21st Dec 20104:40 pmRNSHolding(s) in Company
21st Dec 20104:36 pmRNSTotal Voting Rights
20th Dec 20103:29 pmRNSHolding(s) in Company
17th Dec 20109:51 amRNSResult of General Meeting
26th Nov 20107:00 amRNSHalf Yearly Report
26th Nov 20107:00 amRNSDistribution Agreement: Food DetectiveT in India
17th Nov 20107:00 amRNSPlacing and Acquisition
13th Oct 20107:00 amRNSTrading Statement
19th Aug 20102:32 pmRNSAGM Statement
23rd Jul 201010:20 amRNSHolding(s) in Company
16th Jul 20107:00 amRNSFinal Results
26th May 20107:00 amRNSCo-Tek supply agreement
30th Apr 20102:26 pmRNSHolding(s) in Company
13th Apr 20107:00 amRNSTrading Statement
22nd Dec 20098:43 amRNSDirectorate Change
11th Dec 20097:00 amRNSTrading Statement
27th Nov 20097:00 amRNSHalf Yearly Report
4th Nov 200910:19 amRNSHolding(s) in Company
21st Oct 20094:51 pmRNSEnd of offer period
21st Oct 200910:50 amRNSRule 8.3- Omega Diagnostics Group Plc
20th Oct 200911:52 amRNSRule 8.3- Omega Diagnostics Group Plc
20th Oct 200911:43 amRNSRule 8.3- Omega Diagnostics
19th Oct 20097:00 amRNSStatement re Possible Offer
14th Oct 200911:12 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.